Matritech's cervical cancer test wins US patent:
This article was originally published in Clinica
Executive Summary
Matritech has received a US patent covering its NMP179 protein marker test for cervical cancer. The test is based on the company's Nuclear Matrix Protein (NMP) technology, which correlates levels of NMPs in body fluids to the presence of cancer. It has already shown promising results in recent studies (see Clinica No 840, p 16). The test could improve cancer detection in the early stages when the rate of survival is greater than 90% and also reduce the cost and discomfort associated with traditional Pap smear follow-up procedures such as colposcopy, according to Matritech of Newton, Massachusetts.